Search research articles
Contact Us
Filters
Showing results (41-50 of 64) with videos related to
Page
of 7
Sort By:
American Journal of Hematology
|
July 12, 2002
Acetaminophen and diphenhydramine as premedication for platelet transfusions: a prospective randomized double-blind placebo-controlled trial
Stephen E Wang, Primo N Lara, Angie Lee-Ow, et al.
Cancers
|
January 28, 2026
Phase I Study of Mogamulizumab in Combination with Pembrolizumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma-A National Cancer Institute Experimental Therapeutics Clinical Trials Network (NCI-ETCTN) Trial
Erel Joffe, Anita Kumar, Joseph M Tuscano, et al.
Leukemia & Lymphoma
|
February 20, 2016
A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study
Mark H Kirschbaum, Paul Frankel, Timothy W Synold, et al.
British Journal of Haematology
|
July 10, 2013
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation
Julie M Vose, Thomas M Habermann, Myron S Czuczman, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 14, 2025
Lymphoma Therapy Response Assessment with Low-Dose [<sup>18</sup>F]FDG Total-Body PET/CT
Clemens Mingels, Kevin J Chung, Hande Nalbant, et al.
Molecular Medicine (Cambridge, Mass.)
|
July 26, 2016
Novel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate
Noriko Satake, Connie Duong, Sakiko Yoshida, et al.
Leukemia Research
|
June 6, 2025
A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503)
Brian A Jonas, Samantha C Fisch, Peter T Curtin, et al.
American Journal of Hematology
|
July 13, 2017
Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma
Thomas E Witzig, Pier Luigi Zinzani, Thomas M Habermann, et al.
British Journal of Haematology
|
February 28, 2009
Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma
Thomas M Habermann, Izidore S Lossos, Glen Justice, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 5, 2019
A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
Joseph M Tuscano, Emanual Maverakis, Susan Groshen, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 64) with videos related to
Sort By:
Page
of 7
American Journal of Hematology
|
July 12, 2002
Acetaminophen and diphenhydramine as premedication for platelet transfusions: a prospective randomized double-blind placebo-controlled trial
Stephen E Wang, Primo N Lara, Angie Lee-Ow, et al.
Cancers
|
January 28, 2026
Phase I Study of Mogamulizumab in Combination with Pembrolizumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma-A National Cancer Institute Experimental Therapeutics Clinical Trials Network (NCI-ETCTN) Trial
Erel Joffe, Anita Kumar, Joseph M Tuscano, et al.
Leukemia & Lymphoma
|
February 20, 2016
A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study
Mark H Kirschbaum, Paul Frankel, Timothy W Synold, et al.
British Journal of Haematology
|
July 10, 2013
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation
Julie M Vose, Thomas M Habermann, Myron S Czuczman, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 14, 2025
Lymphoma Therapy Response Assessment with Low-Dose [<sup>18</sup>F]FDG Total-Body PET/CT
Clemens Mingels, Kevin J Chung, Hande Nalbant, et al.
Molecular Medicine (Cambridge, Mass.)
|
July 26, 2016
Novel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate
Noriko Satake, Connie Duong, Sakiko Yoshida, et al.
Leukemia Research
|
June 6, 2025
A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503)
Brian A Jonas, Samantha C Fisch, Peter T Curtin, et al.
American Journal of Hematology
|
July 13, 2017
Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma
Thomas E Witzig, Pier Luigi Zinzani, Thomas M Habermann, et al.
British Journal of Haematology
|
February 28, 2009
Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma
Thomas M Habermann, Izidore S Lossos, Glen Justice, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 5, 2019
A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
Joseph M Tuscano, Emanual Maverakis, Susan Groshen, et al.
Page
of 7